On Monday, Alector Inc (ALEC) stock saw a modest uptick, ending the day at $2.31 which represents a slight increase of $0.15 or 6.94% from the prior close of $2.16. The stock opened at $2.3 and ...

Alector Inc (ALEC) stock saw a decline, ending the day at $2.16 which represents a decrease of $-0.04 or -1.82% from the prior close of $2.2. The stock opened at $2.27 and touched a low of $2.06 ...

The collaboration deal, which could be worth hundreds of millions of dollars, is a “pivotal moment” for Muna Therapeutics, a ...

As of 12:34:05 PM EST. Market Open. Alector stock falls as the phase II INVOKE-2 study evaluating AL002 in slowing disease progression in early Alzheimer's disease fails to meet the primary goal.

Alector's AL002 misses primary endpoint in Alzheimer's trial. BofA downgrades stock, cuts price target, and highlights near-term challenges.

在其他近期新闻中，Alector Inc.遭遇重大挫折，其针对潜在阿尔茨海默病治疗药物AL002的二期INVOKE-2试验未能达到主要终点，导致该项目被终止。这促使Morgan Stanley将Alector的股票评级从"与大盘持平"下调至"减持"，并将目标价下调至3.00美元。尽管如此，H.C.

As previously reported, BofA downgraded Alector (ALEC) to Underperform from Neutral with a price target of $1, down from $9, after ALOO2 missed ...

BofA downgraded Alector (ALEC) to Underperform from Neutral with a price target of $1, down from $9.Don't Miss our Black Friday Offers:Unlock ...

根据最近向美国证券交易委员会提交的文件显示，Alector, Inc. (NASDAQ:ALEC)的首席医疗官Gary Romano出售了14,892股普通股。此次交易发生之际，该公司股票价格接近52周低点2.37美元，过去六个月内已下跌超过50%。根据 InvestingPro 分析，基于公允价值指标，该股票目前似乎被低估。这些股票于2024年12月2日以平均价格2.5194美元售出，总交易价值 ...

Vigil Neuroscience's stock dropped after Alector's AL002 failed in Alzheimer's, raising concerns about VG-3927's efficacy.

根据Alector发布的最新财务报告，公司的营业收入为1534万美元，而净利润则显示出公司面临严重亏损，达到了4222万美元，每股收益为-0.43美元。这样的业绩在生物技术行业中并不罕见，尤其是处于研发阶段的公司，但仍然可能令投资者对于未来的盈利能力产生质疑。此外，该公司目前的毛利为1315万美元，市盈率为-1.44倍，这一数据表明，市场对其未来盈利的预期相对负面。

北京时间2024年12月03日02时39分，Alector, Inc.（ALEC.us）股票出现波动，股价急速跳水5.02%。截至发稿，该股报2.46美元/股，成交量144.382万股， 换手率 1.47%，振幅6.53%。